|
Invitation
China
has been described as "Generic Drugs Country", nearly 97% of Chinese
pharmaceutical companies devote themselves to produce generic drugs.
However, those companies are confronted with gradually increasing
pressure. As it is required that higher quality and regulations of
generic drugs are prescribed by CFDA to strengthen the drug safety in
the market, the Chinese pharmaceutical enterprises are facing the fierce
competition. It is very significant to adapt the changes and improve
the level of generic research and innovation to develop generic quality
conformance evaluation in the future.
The seminar, “The
Opportunities and Challenges of Generic Drugs Under New Circumstances”,
is hosted by Modern Biotechnology & Pharmaceutical Office of
Shanghai Municipality and co-hosted by Shanghai Center of Biomedicine
Development and Shanghai Medicilon Inc. has its opening on June 21at the
Shanghai International Convention Center. The purpose of this seminar
is to establish a platform for exchange and cooperation between the
pharmaceutical colleagues, to share the abroad working experience of
conformance evaluation, to deeply interpret the newly released
regulations by CFDA and to discuss the problems that pharmaceutical
companies are facing now in order to meet the opportunities and
challenges of generic drugs under new circumstances.
Date & Time: 2016 June 21, 13:00-18:00
Address: Yangtze River Hall, Shanghai International Convention Center
(2727 Binjiang Ave, Pudong, Shanghai, China)
Bio-Forum Secretariat
Shanghai medicilon inc
June 2016
|
|
|
|
Guest introduction
|
|
Dr.
Jiangbin Hu, Vice President of Huahai Pharmaceutical and Senior Vice
President of Huahai Pharmaceutical (US), is currently leading the
project of research and development of domestic generic drug in Huahai
Pharmaceutical. Prior to Huahai Pharmaceutical, Dr. Hu served as the
General Manager in USP-China, President of SAPA, medicine research and
management level in multiple international leading corporations, such as
Roche, Bayer, Novartis and etc. Dr. Hu is also appointed as professor
of Beijing University and Shanghai Jiaotong University.
|
|
Dr.
Guodong Li, Vice President of CMC of Shanghai Medicilon Inc. Dr. Li
graduated as Doctor of Pharmacy from Second Military Medical
Universityand had approximately 20 years teaching experiences in
pharmacyand scientific research. Dr. Li served as the Vice President
and Chief Engineer in BIOASIA Pharmaceutical before joining Medicilon.
|
|
Dr.
Lei Tang, Director of Scientific Affairs in Sanofi China and member of
executive committee in SAPA, whoheld the PhD from Washington University,
School of Medicine in St. Louis and Bachelor Degree from Beijing
University. Dr. Tang had worked in Sanofi for over 18 years, focusing
on medicine discovery and development, in charge of global drug
disposition project portfolio management and expertise in bioanalysis,
biomarkers and its transformation.
|
|
Dr.
Hao Wang, Dean of China State Institute of Pharmaceutical Industry,
Vice-Chairman of Pharmaceutical Committee in Chinese Pharmaceutical
Association, Chairman of Pharmaceutical Committee in Shanghai
Pharmaceutical Association, member of pharmaceutical academic committee
of the Chinese State Council, member of Chinese Pharmacopoeia
Commission, who is drug preparation expertise.His main duty is focusing
on research and development of novel pharmaceutical preparation.
|
|
Dr.
Jiansong Yang, General Manager of MOSIM Shanghai, subsidiary company of
Tigermed, who graduated as Doctor of Clinical Pharmacokinetics from
Sheffield University, UK and Bachelor Degree from School of Pharmacy,
Shengyang Pharmaceutical University. Dr. Yang worked in Simcyp UK and
joined GSK China in 2009, responsible for clinical pharmacology.
|
|
|
|
Conference Agenda
|
|
Time
|
Agenda
|
|
13:00-13:30
|
Registration
|
|
13:30-13:40
|
Opening
|
Host：Dr. Chunlin Chen
CEO, Shanghai Medicilon Inc.
|
|
Welcome Speech
|
|
13:40-14:15
|
Topic Report 1：
The Interpretation and Operation Strategy Analysis of Domestic Generic Drug Policy
|
Shanghai Food and Drug Administration
|
|
14:15-14:50
|
Topic Report 2：
The Risks and Countermeasures of Generic Drugs in Clinical BE Research
|
Dr. Jiansong Yang
Hangzhou Tigermed Consulting Co., Ltd
|
|
14:50-15:05
|
Break
|
|
15:05-15:40
|
Topic Report 3：
The Opportunities and Challenges of European Generics Drugs in China
|
Dr. Jiangbin Hu
Vice President of Huahai Pharmaceutical and Senior Vice President of Huahai Pharmaceutical (US)
|
|
15:40-16:25
|
Topic Report 4：
FDA Requirement of CMC on Generic Drugs and Its Conformance Evaluation Studies
|
Dr. Guohua Zhang
CEO, Novast Holdings Ltd.
|
|
16:25-17:30
|
PanelDiscussion：
Generic R & D Strategy
|
Panelists To Be Invited：
Dr. Jiangbin Hu
VP of Huahai Pharmaceutical &SVP of Huahai Pharmaceutical (US)
Dr. Guodong Li, VP of CMC of Shanghai Medicilon Inc.
Dr. ShiwenLin,Director of CMC of Agenus
Dr. Lei Tang,Director of Scientific Affairs in Sanofi China
Dr. Hao Wang,Dean of China State Institute of Pharmaceutical Industry
Dr. Guohua Zhang,CEO, Novast Holdings Ltd.
|
|
17:30-18:00
|
Q&A
|
|
|
Registration
|
Please click the below website to download the registration form.
http://www.medicilon.com.cn/dowland
Fill in the form and email the form to marketing@medicilon.com.cn
Contact: Juan Xu, 86-21-5859-1500 x 8951
PS: Free Registration for the Seminar. If you would like to participate
the Bio-Forum 2016, please note in the registration form. If you
register the seminar successfully, you could enjoy the special price
(CNY 1,800 / person) for the Bio-Forum 2016.
|
|
|
|
|
|
